Mary Stuart

Senior Writer/Market Analyst

30 Years of Experience

About

Mary is a senior writer for MedTech Strategist and the editor of the “Start-Ups to Watch” department. She’s been reporting on medtech business strategies across all clinical areas for over 30 years. Mary is a key driver and expert in identifying important emerging technology and industry trends while backing up these insights with in-depth research including interviews with high-level executives and thought-leading clinicians. It’s the odd news item that makes one go “Huh,” she says, of her track record while reporting about treatments and technologies just as they’re emerging, and clearly articulating what’s different about those technologies. 

Mary has published articles in dynamic therapeutic areas including the paradigm shift in the treatment of heart failure; technological advances in neurology, especially closed-loop neurostimulation as well as new ways that make brain-sensing more widely available; how digital health can get removed healthcare from its silos to improve outcomes in chronic diseases; atrial fibrillation (exhaustively) and lung cancer, the final frontier in interventional medicine, among other diverse topics. A graduate of Smith College, Mary is ever the advocate of the benefits of a liberal arts education.

Articles from Mary Stuart:

Start-Ups

New Phenotyping Tests Slay Obesity Myths

A new set of objective and simple phenotyping tests that categorize patients by four distinct subtypes of obesity is set to disrupt obesity care, by enabling the tailoring of therapy to a patient's syndrome to create care that is more successful and cost-effective. MedTech Strategist interviews the Mayo Clinic’s Andres Acosta, a co-founder of Phenomix Sciences, which is commercializing the tests.

Read Article